Distribution of the Major Cytochrome P450 (CYP) 2C9 Genetic Variants in a Saudi Population

被引:12
|
作者
Mirghani, Rajaa A. [1 ]
Chowdhary, Gulnaz [1 ]
Elghazali, Gehad [1 ,2 ,3 ]
机构
[1] King Saud Bin Abdulaziz Univ Hlth Sci, Fac Med, King Fahad Med City, Riyadh 11393, Saudi Arabia
[2] King Fahad Med City, Dept Immunol, Riyadh, Saudi Arabia
[3] Univ Shendi, Fac Med & Hlth Sci, Shendi, Sudan
关键词
MUTANT ALLELES; P4502C9; POLYMORPHISMS; CYP2C19; PHARMACOKINETICS; FREQUENCIES; OXIDATION; GENOTYPES; LOSARTAN; WARFARIN;
D O I
10.1111/j.1742-7843.2011.00692.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 (CYP) 2C9 is responsible for the metabolism of a number of widely used drugs such as oral anticoagulants, oral antidiabetics and non-steroidal anti-inflammatory drugs. The CYP2C9 is a genetically polymorphic enzyme. The most common allele is CYP2C9*1, while CYP2C9*2 and CYP2C9*3 are the less-frequent variants. The activity of the enzyme encoded by either CYP2C9 *2 or *3 variant is lower compared with that of the CYP2C9*1. The metabolism of most of the CYP2C9 substrates decreases in varying degrees in subjects carrying the CYP2C9 *2 or *3 allele. The aim of this study was to investigate the frequencies of the major variants of the CYP2C9 in Saudi Arabians.
引用
收藏
页码:111 / 114
页数:4
相关论文
共 50 条
  • [21] Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China
    Yang, Z. F.
    Cui, H. W.
    Hasi, T.
    Jia, S. Q.
    Gong, M. L.
    Su, X. L.
    GENETICS AND MOLECULAR RESEARCH, 2010, 9 (03) : 1844 - 1851
  • [22] Cytochrome P450 2c9 (CYP2C9) metabolic capacity in people with and without cancer.
    Shord, S. S.
    Cavallari, L. H.
    Viana, M. A.
    Momary, K.
    Molokie, R. E.
    Neceskas, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S50 - S51
  • [23] Regulation of cytochrome P450 (CYP) 2C9 expression in human hepatocytes by various xenobiotics.
    Shord, SS
    Gilbert, D
    Hamilton, G
    Faucette, S
    Clarke, M
    Pescatore, S
    Jolley, S
    Lindley, C
    LeCluyse, EL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P29 - P29
  • [24] Effects of Cytochrome P450 2C9 Polymorphism on Bosentan Metabolism
    Chen, Mengchun
    Zhang, Youting
    Pan, Peipei
    Wang, Li
    Zhan, Yunyun
    Jin, Hui
    Xia, Mengmin
    Wang, Xianqin
    Dai, Dapeng
    Cai, Jianping
    Hu, Guoxin
    DRUG METABOLISM AND DISPOSITION, 2014, 42 (11) : 1820 - 1825
  • [25] Kinetics of cytochrome p450 2C9 inhibition by fluoxetine and norfluoxetine
    Tracy, TS
    Grimm, DL
    FASEB JOURNAL, 2003, 17 (04): : A611 - A611
  • [26] Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs -: Clinical relevance
    Kirchheiner, J
    Roots, I
    Goldammer, M
    Rosenkranz, B
    Brockmöller, J
    CLINICAL PHARMACOKINETICS, 2005, 44 (12) : 1209 - 1225
  • [27] Role of Residue 90 in Catalysis of Cytochrome P450 2C9
    Wang Ying
    Zhou Yi-han
    Guo Ying-jie
    Xu Xue-lian
    Si Da-yong
    Zhou Hui
    Li Ze-sheng
    CHEMICAL RESEARCH IN CHINESE UNIVERSITIES, 2009, 25 (06) : 904 - 908
  • [28] Polymorphisms of human cytochrome P450 2C9 and the functional relevance
    Zhou, Shu-Feng
    Zhou, Zhi-Wei
    Huang, Min
    TOXICOLOGY, 2010, 278 (02) : 165 - 188
  • [29] Role of Residue 90 in Catalysis of Cytochrome P450 2C9
    WANG Ying1
    ChemicalResearchinChineseUniversities, 2009, 25 (06) : 904 - 908
  • [30] Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance
    Wang, Bo
    Wang, Jing
    Huang, Shui-Qing
    Su, Hai-Hao
    Zhou, Shu-Feng
    CURRENT DRUG METABOLISM, 2009, 10 (07) : 781 - 834